(R)-apomorphine derivatives (AstraZeneca)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Name(R)-apomorphine derivatives (AstraZeneca)
Drug Alias Nameapomorphine (AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 7 (5-HT7) receptor modulatorsSerotonin 1a (5-HT1a) receptor modulatorsDopamine D2 receptor modulators
TargetsSerotonin 1a (5-HT1a) receptorDopamine D2 receptorSerotonin 7 (5-HT7) receptor
Therapy Area/IndicationsCentral Nervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsCentral Nervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A